Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-99a mimic
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
miR-99a mimic is a synthetic, double-stranded RNA oligonucleotide designed to replicate the biological activity of the endogenous tumor-suppressive microRNA, miR-99a. In various malignancies, particularly non-small cell lung cancer (NSCLC), miR-99a expression is frequently downregulated, which contributes to the overexpression of oncogenic targets. The miR-99a mimic functions by binding to the 3' untranslated region (UTR) of specific messenger RNAs, such as the insulin-like growth factor 1 receptor (IGF-1R) and mTOR, leading to their translational inhibition or degradation. This restoration of miR-99a activity results in the suppression of cancer cell proliferation, migration, and invasion, and can inhibit epithelial-to-mesenchymal transition (EMT). It is primarily utilized as a tool in preclinical oncology research to explore miRNA replacement therapies.
- Other names
- microRNA-99a mimicmicroRNA99a mimicmicroRNA 99a mimicmiRNA-99a mimicmiRNA99a mimicmiRNA 99a mimichsa-miR-99a mimichsa-miR99a mimichsa-miR 99a mimic
02
Targets
IGF-1R (Insulin-like growth factor 1 receptor)mTOR (Mammalian target of rapamycin kinase)
Beyond the preview
Go deeper on miR-99a mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-99a mimic.